World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
81
Citations
34308
World Ranking
16415
National Ranking
517

Overview

Narikazu Boku is affiliated with St. Marianna University School of Medicine in Japan and has a research focus primarily within the field of Medicine. Their work spans multiple subfields, including Pulmonary and Respiratory Medicine, Oncology, Surgery, Gastroenterology, and Epidemiology.

The scientist's research covers several major topics such as:

  • Gastric Cancer Management and Outcomes
  • Colorectal Cancer Treatments and Studies
  • Gastrointestinal Tumor Research and Treatment
  • Metastasis and carcinoma case studies
  • Cancer Immunotherapy and Biomarkers
  • Esophageal Cancer Research and Treatment
  • Cancer Treatment and Pharmacology

Narikazu Boku has published extensively in leading oncology and medical journals. Frequent publication venues include:

  • Journal of Clinical Oncology
  • Gastric Cancer
  • Annals of Oncology
  • International Journal of Clinical Oncology
  • Research Square

Collaborations are also a notable aspect of their academic work. Prominent frequent co-authors include:

  • Masanori Terashima
  • Takaki Yoshikawa
  • Atsuo Takashima
  • Hirokazu Shoji
  • Ken Kato

Among the recent papers authored or co-authored by Narikazu Boku are:

  • "Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial", 2022, The Lancet Oncology
  • "Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100", 2020, Journal of Clinical Oncology
  • "Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study)", 2020, Journal of Clinical Oncology
  • "Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial", 2020, Gastric Cancer
  • "LBA7_PR Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study", 2020, Annals of Oncology

Best Publications

  • Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer

    Toshiaki Watanabe;Michio Itabashi;Yasuhiro Shimada;Shinji Tanaka

  • Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

    Yoon Koo Kang;Narikazu Boku;Taroh Satoh;Min Hee Ryu

  • Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)

    Katsuhiko Uesaka;Narikazu Boku;Akira Fukutomi;Yukiyasu Okamura

  • Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study

    Hideki Ueno;Tatsuya Ioka;Masafumi Ikeda;Shinichi Ohkawa

  • Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.

    Narikazu Boku;Seiichiro Yamamoto;Haruhiko Fukuda;Kuniaki Shirao

  • Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer

    Toshiaki Watanabe;Michio Itabashi;Yasuhiro Shimada;Shinji Tanaka

  • Randomized Phase III Trial of Fluorouracil Alone Versus Fluorouracil Plus Cisplatin Versus Uracil and Tegafur Plus Mitomycin in Patients With Unresectable, Advanced Gastric Cancer: The Japan Clinical Oncology Group Study (JCOG9205)

    Atsushi Ohtsu;Yasuhiro Shimada;Kuniaki Shirao;Narikazu Boku

  • Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial

    Shuichi Hironaka;Shinya Ueda;Hirofumi Yasui;Tomohiro Nishina

  • New endoscopic treatment for intramucosal gastric tumors using an insulated-tip diathermic knife.

    M. Ohkuwa;K. Hosokawa;N. Boku;A. Ohtu

  • Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.

    Yung Jue Bang;E. Yañez Ruiz;E. Van Cutsem;K. W. Lee

  • Definitive Chemoradiotherapy for T4 and/or M1 Lymph Node Squamous Cell Carcinoma of the Esophagus

    Atsushi Ohtsu;Narikazu Boku;Kei Muro;Keisho Chin

  • Long-Term Toxicity After Definitive Chemoradiotherapy for Squamous Cell Carcinoma of the Thoracic Esophagus

    Satoshi Ishikura;Keiji Nihei;Atsushi Ohtsu;Narikazu Boku

  • Phase II Study of a Combination of Irinotecan and Cisplatin Against Metastatic Gastric Cancer

    Narikazu Boku;Atsushi Ohtsu;Yasuhiro Shimada;Kuniaki Shirao

  • HER2-positive gastric cancer.

    Narikazu Boku

  • Esophageal stenosis after endoscopic mucosal resection of superficial esophageal lesions

    Chikatoshi Katada;Manabu Muto;Tetsuro Manabe;Narikazu Boku

  • Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).

    Ken Kato;Kei Muro;Keiko Minashi;Atsushi Ohtsu

  • Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer

    W Koizumi;S Tanabe;K Saigenji;A Ohtsu

  • A new technique for endoscopic mucosal resection with an insulated-tip electrosurgical knife improves the completeness of resection of intramucosal gastric neoplasms

    Shin'ichi Miyamoto;Manabu Muto;Yasuo Hamamoto;Narikazu Boku

  • Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial

    Yung Jue Bang;Rui Hua Xu;Keisho Chin;Keun Wook Lee

  • Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer.

    Tomonori Yano;Toshihiko Doi;Atsushi Ohtsu;Narikazu Boku

Frequent Co-Authors

Atsushi Ohtsu
Atsushi Ohtsu Juntendo University
Kei Muro
Kei Muro National Cancer Research Institute, UK
Mitsuru Sasako
Mitsuru Sasako Hyogo College of Medicine
Satoshi Morita
Satoshi Morita Kyoto University
Takuji Okusaka
Takuji Okusaka National Cancer Centre
Takayuki Yoshino
Takayuki Yoshino University of Tsukuba
Junji Furuse
Junji Furuse Kyorin University
Toshihiko Doi
Toshihiko Doi Okayama University
Yoon-Koo Kang
Yoon-Koo Kang Asan Medical Center
Kazuto Nishio
Kazuto Nishio Kindai University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing Medicine in the USA opens doors to a wide range of healthcare careers. For students seeking alternative options online, there are several flexible pathways to consider. For example, direct entry msn programs for non-nurses online allow individuals with non-nursing backgrounds to earn a master's degree in nursing and enter the field faster.

If you're looking to become a registered nurse, some schools are renowned for being accessible. Researching the easiest rn program to get into can help you identify institutions with higher acceptance rates or fewer admission barriers.

For those interested in health administration rather than patient care, online medical coding classes with financial aid offer a cost-effective way to start a career in medical billing and coding.

There are also nursing programs that simplify admission requirements. For example, you can find an lpn program without teas test, helping you quickly start a practical nursing career without additional standardized exams.

These alternative pathways make it easier than ever for students from diverse backgrounds to enter the growing healthcare field.

Best Scientists Citing Narikazu Boku

Trending Scientists

Recently Published Articles